In the BioHarmony Drug Report Database
Dostinex (cabergoline) is a small molecule pharmaceutical. Cabergoline was first approved as Dostinex on 1996-12-23. It is used to treat adenoma, hyperprolactinemia, and parkinson disease in the USA. It is known to target D(2) dopamine receptor, D(3) dopamine receptor, D(1B) dopamine receptor, alpha-1A adrenergic receptor, alpha-2A adrenergic receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1D, alpha-2C adrenergic receptor, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2B, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C.
Image (chem structure or protein)